Related Experiment Video
Updated: Feb 3, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
1.5K
CXCL9 chemokine in ulcerative colitis.
1Department of Clinical and Experimental Medicine, University of Pisa.
La Clinica Terapeutica
|November 6, 2018
Summary
Chemokine ligand 9 (CXCL9) is elevated in ulcerative colitis (UC), contributing to inflammation. CXCL9 may serve as a biomarker for UC disease activity and treatment response.
Area of Science:
- Immunology
- Gastroenterology
Background:
- Ulcerative Colitis (UC) involves complex inflammatory mechanisms.
- Chemokines play a critical role in immune cell trafficking and inflammation.
Purpose of the Study:
- To review the role of CXCL9 in Ulcerative Colitis (UC).
- To understand UC inflammation mechanisms.
- To assess Th1-chemokines as potential UC disease markers.
Main Methods:
- Narrative review of existing literature.
- Analysis of studies on chemokine (C-X-C motif) receptor (CXCR)3 and its ligand CXCL9 expression.
- Examination of CXCL9 levels in experimental colitis and human UC.
Main Results:
- CXCL9 and CXCR3 are overexpressed in UC intestinal mucosa, lymphocytes, macrophages, and epithelial cells.
- Interferon-gamma (IFN-γ) upregulates CXCL9 in colonic epithelial cells.
- CXCL9 facilitates mononuclear cell and granulocyte recruitment, sustaining UC inflammation.
Conclusions:
- CXCL9 is implicated in UC pathogenesis.
- Serum CXCL9 levels correlate with UC disease activity, suggesting potential as a treatment response marker.
- Targeting CXCL9 may offer a therapeutic strategy for moderate-to-severe UC.
More Related Videos
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
10.6K
15:49Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
32.7K
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
519
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
519
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
991
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
991
01:28Peptic Ulcer Disease II: Pathophysiology
2.1K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.1K
01:30Peptic Ulcer Disease I: Introduction
835
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
835
01:26Peptic Ulcer Disease IV: Management
500
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
500
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K